Table 2.
Data regarding conception within the study group n = 31 (MS* patients exposed to TFL** >30 consecutive days when becoming/partner becoming pregnant and up to 2 years after discontinuation of TFL treatment), and the reference group (n = 124).
| Study group n = 31 | Reference group n = 124 | |||
|---|---|---|---|---|
| Male (n = 18) | Female (n = 13) | Male (n = 72) | Female (n = 52) | |
| AGE AT CONCEPTION | ||||
| 19–24 | 0 | 3 | 0 | 12 |
| 25–30 | 3 | 6 | 13 | 24 |
| 31–35 | 10 | 3 | 40 | 12 |
| 36–40 | 3 | 1 | 12 | 4 |
| >40 | 2 | 0 | 8 | 0 |
| Mean (min;max)sd*** | 34.1 (27;42)3.9 |
28.5 (19;38)4.8 |
34.1 (27;42)3.9 |
28.5 (19;38)4.6 |
| DURATION ON TFL AT CONCEPTION IN DAYS | ||||
| 31–90 | 5 | 2 | N/A**** | N/A |
| 91–180 | 4 | 3 | N/A | N/A |
| 181–365 | 5 | 1 | N/A | N/A |
| >365 | 3 | 1 | N/A | N/A |
| Mean (min;max)sd | 198 (34;463)148.1 |
154 (47;380)111.3 |
N/A | N/A |
| CONCEPTION AFTER TREATMENT STOP IN DAYS | ||||
| 31–90 | 0 | 1 | N/A | N/A |
| 91–180 | 0 | 1 | N/A | N/A |
| 181–365 | 1 | 2 | N/A | N/A |
| 366–730 | 0 | 2 | N/A | N/A |
| Mean (min;max)sd*** | 343 | 316.5 (35;688)234.8 |
N/A | N/A |
*
Mulitple sclerosis.
**
Teriflunomide.
***
Standard deviation.
****
Not applicable.